Literature DB >> 20542598

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.

J Nettiksimmons1, D Harvey, J Brewer, O Carmichael, C DeCarli, C R Jack, R Petersen, L M Shaw, J Q Trojanowski, M W Weiner, L Beckett.   

Abstract

Cerebrospinal fluid (CSF) and structural magnetic resonance imaging (MRI) show patterns of change in Alzheimer's disease (AD) that precede dementia. The Alzheimer's Disease Neuroimaging Initiative (ADNI) studied normal controls (NC), subjects with mild cognitive impairment (MCI), and subjects with AD to identify patterns of biomarkers to aid in early diagnosis and effective treatment of AD. Two hundred twenty-two NC underwent baseline MRI and clinical examination at baseline and at least one follow-up. One hundred twelve also provided CSF at baseline. Unsupervised clustering based on initial CSF and MRI measures was used to identify clusters of participants with similar profiles. Repeated measures regression modeling assessed the relationship of individual measures, and of cluster membership, to cognitive change over 3 years. Most individuals showed little cognitive change. Individual biomarkers had limited predictive value for cognitive decline, but membership in the cluster with the most extreme profile was associated with more rapid decline in ADAS-cog. Subtypes among NC based on multiple biomarkers may represent the earliest stages of subclinical cognitive decline and AD. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542598      PMCID: PMC2902683          DOI: 10.1016/j.neurobiolaging.2010.04.025

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

1.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-11-08       Impact factor: 6.556

2.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

3.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

4.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Authors:  Alessia Maddalena; Andreas Papassotiropoulos; Britta Müller-Tillmanns; Hans H Jung; Thomas Hegi; Roger M Nitsch; Christoph Hock
Journal:  Arch Neurol       Date:  2003-09

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease.

Authors:  Christine Fennema-Notestine; Donald J Hagler; Linda K McEvoy; Adam S Fleisher; Elaine H Wu; David S Karow; Anders M Dale
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

Review 7.  Biomarkers for early detection of Alzheimer pathology.

Authors:  C M Clark; C Davatzikos; A Borthakur; A Newberg; S Leight; V M-Y Lee; J Q Trojanowski
Journal:  Neurosignals       Date:  2007-12-05

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

Review 9.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

Review 10.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.

Authors:  Leslie M Shaw; Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Drug Discov       Date:  2007-03-09       Impact factor: 84.694

View more
  42 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

3.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

Review 4.  Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Trends Cogn Sci       Date:  2013-09-09       Impact factor: 20.229

5.  Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Authors:  Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson
Journal:  Brain       Date:  2016-06-20       Impact factor: 13.501

6.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

7.  Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage.

Authors:  Jasmine Nettiksimmons; Laurel Beckett; Christopher Schwarz; Owen Carmichael; Evan Fletcher; Charles Decarli
Journal:  Psychol Aging       Date:  2013-03

8.  Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease.

Authors:  Kwangsik Nho; Shannon L Risacher; Paul K Crane; Charles DeCarli; M Maria Glymour; Christian Habeck; Sungeun Kim; Grace J Lee; Elizabeth Mormino; Shubhabrata Mukherjee; Li Shen; John D West; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

Review 9.  A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Biol Psychiatry       Date:  2013-11-28       Impact factor: 13.382

10.  Latent feature representation with stacked auto-encoder for AD/MCI diagnosis.

Authors:  Heung-Il Suk; Seong-Whan Lee; Dinggang Shen
Journal:  Brain Struct Funct       Date:  2013-12-22       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.